| Timothy Geschrey, | |
|
660 S Grand Ave, Sun Prairie, WI 53590-9832 | |
| (608) 834-5601 | |
| Not Available |
| Full Name | Timothy Geschrey |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 660 S Grand Ave, Sun Prairie, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023494465 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 051298823 (Illinois) | Secondary |
| 183500000X | Pharmacist | 1810440 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Timothy Geschrey, 660 S Grand Ave, Sun Prairie, WI 53590-9832 Ph: (608) 834-5601 | Timothy Geschrey, 660 S Grand Ave, Sun Prairie, WI 53590-9832 Ph: (608) 834-5601 |
News Archive
BioTime, Inc. today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM).
"Up to a quarter of a million women and girls in Southeast Asia, mostly adolescents, are forced into prostitution each year and face violence and the prospect of contracting HIV/AIDS," researchers said on Wednesday in a report about criminal activity in Cambodia, Indonesia and Thailand, Reuters reports.
Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 8 days ago
Jeffrey Zietlow, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2538 Ironwood Dr, Sun Prairie, WI 53590 Phone: 608-837-2867 | |
Ryan Dilley, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 302 S Grand Ave, Sun Prairie, WI 53590 Phone: 608-837-5949 | |
Renae E Pinter, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 660 S Grand Ave, Target Pharmacy T-2491, Sun Prairie, WI 53590 Phone: 608-834-5601 Fax: 608-834-5601 | |
Ms. Cheryl A Waterworth, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 275 Davison Dr, Sun Prairie, WI 53590 Phone: 608-837-8566 | |
Dr. Scott Proebstle, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 275 Davison Dr, Sun Prairie, WI 53590 Phone: 608-837-8566 | |
Jason Douglas Crawford, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 660 S Grand Ave, Sun Prairie, WI 53590 Phone: 608-834-5601 |